Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer.
BACKGROUND
Suppression of thyroid stimulating hormone (TSH) below the normal range with administration of L-thyroxine has been shown to improve survival in patients treated for thyroid cancer (TC). Although most TC patients require long-term TSH suppression therapy, the effect of this treatment on cardiac rhythm remains unknown. A cross-sectional study was conducted to determine the prevalence of atrial fibrillation (AF) in TC patients on TSH suppressive therapy.


METHODS
All TC patients seen between June 2009 and March 2010 through a multidisciplinary thyroid oncology clinic, Halifax, Nova Scotia, Canada, for whom TSH suppressive therapy had previously been recommended, were recruited into the study. Each patient underwent an electrocardiogram and filled out a questionnaire relevant to causes, signs/symptoms of AF and/or its complications. The prevalence of AF in this population then was compared against the published prevalence of AF in general populations.


RESULTS
A total of 351 patients were seen in the thyroid clinic of which 136 patients met the inclusion criteria for the study. The mean age was 52 years, 85% were female, and mean follow-up duration prior to recruitment was 11 years. The mean TSH was 0.17 mIU/L (Normal: 0.35 - 5.5 mIU/L). There were 14 patients found to have AF (two patients had long-standing persistent AF and 12 patients had paroxysmal AF). The mean ages of patients with and without AF were 61.6 years and 51.4 years, respectively (P = 0.01). Prevalence of AF in the study group was 10.3%; the rate of AF in the TC patients aged 60 years and over (17.5%) was higher than the rate of AF in published data in people 60 years and over (P < 0.001). AF was diagnosed after the initiation of the TSH suppression therapy in all except one patient.


CONCLUSIONS
TSH suppression in thyroid cancer is associated with a high prevalence of AF, particularly in older individuals.
Department of Medicine, Dalhousie University, Halifax, NS, Canada.
Abdulgani
A
Abonowara
Ata
A
Quraishi
John L
JL
Sapp
Mohammed H
MH
Alqambar
Adi
A
Saric
Colleen M
CM
O'Connell
Murali M
MM
Rajaraman
Robert D
RD
Hart
Syed A
SA
Imran
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000139:chemically induced* / Q000453:epidemiology; D003430:Cross-Sectional Studies; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D013972:Thyrotropin / Q000037:antagonists & inhibitors*; D013974:Thyroxine / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
D013972:Thyrotropin; D013974:Thyroxine